Orlando、FLにおける卵巣がんの臨床試験
Orlandoとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第3相
- Advent Health, Orlando
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Advent Health, Orlando
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16マイル先
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- AdventHealth Cancer Institute, Orlando
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
被験者募集中観察研究
- Orlando Health, Orlando
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0308 - Advent Health, Orlando
- Site 0241 - Florida Cancer Specialist - North, Altamonte Springs · 9マイル先
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- AdventHealth Orlando, Orlando
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Sara Cannon Research Institute Lake Nona, Orlando
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
被験者募集中第3相
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Florida Cancer Specialists - Lake Nona, Orlando
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- Advent Health Cancer Institute, Orlando
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
被験者募集中第1相
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
被験者募集中第1/2相
- Florida Cancer Specialists, Orlando
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- AdventHealth Cancer Institute, Orlando
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · 10マイル先
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Florida Cancer Specialists, Orlando
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
被験者募集中第3相
- AdventHealth Cancer Institute, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Florida Cancer Specialists, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Orlando
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #8, Orlando
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Orlandoにおける他の研究
- 非小細胞肺癌44件の研究
- 肥満症32件の研究
- 転移性癌29件の研究
- 過体重27件の研究
- アルツハイマー病25件の研究
- 2型糖尿病25件の研究
- がん（全種類）24件の研究
- 乳がん23件の研究
- 潰瘍性大腸炎22件の研究
- 肺がん21件の研究
- 大腸癌19件の研究
- 大うつ病性障害19件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。